The GeneSolve study, recently funded by Genome British Columbia, examines the value of genomic sequencing for diagnosing childhood rare diseases. Through a cross-institutional collaboration with Oxford University, PACER is developing new ways to address the high levels of uncertainty introduced by multi-omics technologies. This multi-country approach to economic analyses will support the timely and appropriate adoption of genomics for better diagnosing and treating children with rare diseases across jurisdictions.
Project funding announcement: https://www.genomebc.ca/quantifying-the-value-of-genomics-driven-healthcare-for-children-with-rare-diseases-a-multi-country-economic-analysis/